^
    10d
    Safety & Efficacy of Genakumab in Patients With Frequent Flares (clinicaltrials.gov)
    P3, N=302, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Jul 2024 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    genakumab (Gensci048)
    10d
    Gensci 048-202: Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy (clinicaltrials.gov)
    P2, N=106, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> May 2024
    Trial completion • Trial completion date
    |
    genakumab (Gensci048)
    10d
    Gensci 048-203: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare (clinicaltrials.gov)
    P2, N=106, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    genakumab (Gensci048)
    10d
    A Bioequivalence Study of Two Different Dosage Form of Genakumab (clinicaltrials.gov)
    P1, N=178, Active, not recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    genakumab (Gensci048)
    2ms
    To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. (clinicaltrials.gov)
    P=N/A, N=221, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Phase classification: P2b --> PN/A | N=30 --> 221 | Trial completion date: Oct 2024 --> Jun 2028 | Trial primary completion date: Jul 2024 --> Mar 2028
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    genakumab (Gensci048)
    11ms
    A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P2 trial
    |
    genakumab (Gensci048)
    over2years
    Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=120, Recruiting, GeneScience Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
    |
    Tevimbra (tislelizumab-jsgr) • genakumab (Gensci048)
    over2years
    Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, GeneScience Pharmaceuticals Co., Ltd.
    New P1 trial • Combination therapy
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
    |
    Tevimbra (tislelizumab-jsgr) • genakumab (Gensci048)